| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
NDA Filing example | NDA | — | Subscribe to access the data. | Small Molecules | Oncology | ||
NDA Filing example | NDA | — | Subscribe to access the data. | Small Molecules | Oncology | ||
NDA Filing example | NDA | — | Subscribe to access the data. | Small Molecules | Oncology |
Recent Updates
Recently added Catalysts
PMV Pharmaceuticals, Inc.$1.24
-0.04 (-3.23%)
C 53Pipeline Score Fair Value Biotech · Clinical
Market Cap
67.20 M
EPS
-1.48
P/E Ratio
-
Value Trade
314.67 K
SEC Financials
Q1 2026Dilution Risk
25%R&D Expenses
15.33 M
Operating CF
-19.68 M
Total Assets
96.56 M
Total Liabilities
8.60 M
Equity
87.97 M
D/E Ratio
12,345
-4.55 %
Week
-13.7 %
1 Month
18.87 %
3 Month
-5.26 %
6 Month
-96.49 %
5 Year
-96.4 %
All Time
Cash Data
Cash Position
93.55 M
Monthly Burn
6.56 M
Runway
12.6 mo
Burn Trend
StableSEC Filing
May 12, 2026
Overview
Volume
171.97 K
52 Week Range
0.85 - 1.88
% held by Insiders
8.32 %
% held by Institutions
64.35 %
Enterprise Value
-26.06 M
Total Shares
53.34 M
Short %
6.75 %
Float Shares
43.10 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for PMV Pharmaceuticals, Inc.
154Total events
2Upcoming
18Tier-1 (high impact)
2020 – 2027Coverage
Upcoming catalysts 2
Event history 152
Jun 4, 2026
◆Management ChangeCorporate
Laurie Stelzer appointed Chair of the Board, succeeding Rich Heyman
May 12, 2026
▲Orphan Drug DesignationrezatapoptDesignation
Rezatapopt granted Orphan Drug Designation by FDA for TP53 Y220C positive ovarian cancer
TP53 Y220C positive ovarian cancer, fallopian tube cancer, and primary peritoneal cancersource ↗
May 12, 2026
▲PublicationrezatapoptPresentation
Phase 1 results of rezatapopt published in New England Journal of Medicine
TP53 Y220C-mutated advanced solid tumorssource ↗
Apr 12, 2026
▲Oral PresentationrezatapoptPresentation
Updated Phase 2 PYNNACLE results presented at SGO Annual Meeting
platinum-resistant/refractory ovarian cancer with TP53 Y220C mutationsource ↗
Mar 6, 2026
◆Enrollment UpdaterezatapoptTrial
Enrollment on track in Phase 2 pivotal portion of PYNNACLE trial
platinum-resistant/refractory ovarian cancer with TP53 Y220C mutationsource ↗
Mar 2, 2026
▲Orphan Drug DesignationrezatapoptDesignation
FDA granted Orphan Drug Designation to rezatapopt for TP53 Y220C positive ovarian cancer
TP53 Y220C positive ovarian cancer, fallopian tube cancer, and primary peritoneal cancersource ↗
Feb 26, 2026
▲PublicationrezatapoptPresentation
Phase 1 results of rezatapopt published in New England Journal of Medicine
advanced solid tumors with TP53Y220C mutationsource ↗
2026
▲Oral PresentationrezatapoptPresentation
New findings from PYNNACLE Phase 2 presented at 2026 ESGO Congress
TP53 Y220C positive ovarian cancersource ↗
Q1 2026
●Enrollment MilestonerezatapoptTrial
Plan to enroll additional 20-25 platinum resistant/refractory ovarian cancer patients
platinum resistant/refractory ovarian cancersource ↗
Q1 2026
●Enrollment CompleterezatapoptTrial
Expected completion of enrollment in Phase 2 portion of PYNNACLE study
advanced solid tumors with TP53 Y220C mutationsource ↗
Drug Pipeline Intelligence
C53
Pipeline Score $136M
Pipeline ValueFair Value
Valuation Signal2
Drugs Scored2.0x
rNPV / MCap Top 80%
Micro Cap (rank 183 of 911)
Percentile RankPMV Pharmaceuticals, Inc. carries a moderate pipeline score (53/100), with $3.5B risk-adjusted pipeline value, led by rezatapopt in Advanced Solid Tumor (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| rezatapopt Small molecule | Advanced Solid Tumor | Phase 1 | NCT04585750 | 10% | $3.4B | RECRUITING | 300 | VERY_FAST | C (44) | Dec 31, 2027 | LOW_RISK | LOW Jun 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
rezatapopt Fast TrackOrphan | platinum-resistant/refractory ovarian cancer with TP53 Y220C mutation | Phase 2 | 2026-05-12 | Overall response rate (ORR) of 44% (32/72 patients), including one confirmed complete response, 31 confirmed partial responses. The median time to response was 1.3 months and the median duration of response was 8.2 months. ORR increased to 46% (34/74) after additional unconfirmed partial responses. Read More | PMV Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Highlights Read More | |
rezatapopt Fast TrackOrphan | platinum-resistant/refractory ovarian cancer with TP53 Y220C mutation | Phase 2 | 2026-05-12 | Overall response rate (ORR) of 44% (32/72 patients), including one confirmed complete response, 31 confirmed partial responses. The median time to response was 1.3 months and the median duration of response was 8.2 months. ORR increased to 46% (34/74) after additional unconfirmed partial responses. Read More | PMV Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Highlights Read More | |
rezatapopt Fast TrackOrphan | platinum-resistant/refractory ovarian cancer with TP53 Y220C mutation | Phase 2 | 2026-05-12 | Overall response rate (ORR) of 44% (32/72 patients), including one confirmed complete response, 31 confirmed partial responses. The median time to response was 1.3 months and the median duration of response was 8.2 months. ORR increased to 46% (34/74) after additional unconfirmed partial responses. Read More | PMV Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Highlights Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in PMVP
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
PMVP Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
PMVPPMV Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Highlights
PMV Pharmaceuticals reported positive developments for rezatapopt, which received Orphan Drug Designation for treating TP53 Y220C positive ovarian cancer. The company plans to submit a New Drug Application for this indication in early 2027. Recent data published in the New England Journal of Medicine demonstrated the drug's potential effectiveness in advanced solid tumors. Financially, PMV ended Q1 2026 with $93.5 million in cash.
Read more →PMVPPMV Pharmaceuticals, Inc. Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) (in thousands, except share and per share amounts) Three Months Ended
PMV Pharmaceuticals, Inc. has reported its financial results for Q1 2026, highlighting a net loss of $18 million and a decrease in cash reserves. The company received Orphan Drug Designation for its lead candidate, rezatapopt, targeted at TP53 Y220C positive ovarian cancer. Successful preliminary results from the FDA-regarded PYNNACLE study were published, demonstrating a 44% overall response rate in patients. PMV Pharma plans to submit a New Drug Application for rezatapopt aimed at treating platinum-resistant/refractory ovarian cancer in early 2027.
Read more →PMVPPMV Pharmaceuticals Announces Board Chair Transition
PMV Pharmaceuticals has announced a leadership transition on its Board of Directors, appointing Laurie Stelzer as the new Chair, effective June 4, 2026. Ms. Stelzer, who has over 25 years of experience in finance and business development, takes over from Dr. Rich Heyman, who will not stand for reelection. This leadership change comes as the company progresses with its ongoing PYNNACLE clinical trial evaluating rezatapopt for treating advanced solid tumors. PMV is also planning to submit a New Drug Application for rezatapopt in the first quarter of 2027.
Read more →PMVP▲ +7.2%on this news
PMV Pharmaceuticals Reports Full Year 2025 Financial Results and Corporate Highlights
PMV Pharmaceuticals reported its financial results for the full year 2025, highlighting progress in the Phase 2 PYNNACLE clinical trial for rezatapopt, a treatment for platinum-resistant ovarian cancer. The drug has been granted Orphan Drug Designation by the FDA, indicating potential market advantages. Financially, the company reported a net loss of $77.7 million, with cash reserves totaling $112.9 million, expected to last through mid-2027. The company aims to submit a New Drug Application for rezatapopt in early 2027.
Read more →PMVP▲ +7.2%on this news
PMV Pharmaceuticals, Inc. Condensed Consolidated Statements of Opera tions and Comprehensive Loss (unaudited) (in thousands, except share and per share amounts) Years ended
PMV Pharmaceuticals announced its financial results for the year ending December 31, 2025, highlighting key developments in their clinical pipeline. The company is progressing with the Phase 2 PYNNACLE trial of rezatapopt for treating platinum-resistant ovarian cancer patients with a TP53 Y220C mutation. The FDA has granted orphan drug status to this candidate, which has demonstrated positive early results. However, the company reported a significant net loss and a decrease in cash reserves compared to the previous year.
Read more →PMVP▲ +22.3%on this news· ran to +52% by day 1
New England Journal of Medicine Publishes First-in-Human Rezatapopt Data Showing Selective Reactivation of Mutant p53 in Advanced Solid Tumors
PMV Pharmaceuticals announced the publication of Phase 1 data for rezatapopt in the New England Journal of Medicine. The study involved 77 patients with advanced solid tumors and showed promising antitumor activity linked to the p53 Y220C mutation. The findings support the company's strategy for a Phase 2 trial and a future New Drug Application for ovarian cancer treatment.
Read more →PMVP▲ +6.8%on this news
PMV Pharmaceuticals Reports Third Quarter 2025 Financial Results and Corporate Highlights
PMV Pharmaceuticals reported its third quarter 2025 financial results, highlighting a cash position of $129.3 million. The company is advancing its PYNNACLE clinical trial for rezatapopt, a treatment targeting p53 mutations in ovarian cancer. CEO David Mack expressed optimism about submitting an NDA in early 2027. However, the company faces increasing operational costs.
Read more →PMVPPMV Pharmaceuticals Announces Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation
PMV Pharmaceuticals has announced updated interim data from the Phase 2 PYNNACLE trial, showcasing the efficacy of rezatapopt in patients with advanced solid tumors carrying the TP53 Y220C mutation. The results indicate significant clinical activity, particularly in platinum-resistant ovarian cancer. The company plans to submit a New Drug Application in early 2027, aiming to address the urgent need for better treatment options.
Read more →PMVP▲ +7.6%on this news
PMV Pharmaceuticals to Present Rezatapopt Pivotal Phase 2 Initial Analysis and Natural History Study Results at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
PMV Pharmaceuticals will present pivotal findings on rezatapopt at the AACR-NCI-EORTC conference. The oral presentation will focus on the initial analysis of the PYNNACLE Phase 2 trial for patients with advanced solid tumors harboring a TP53 Y220C mutation. Additionally, a poster will detail the natural history and prognostic value of this mutation in advanced tumors.
Read more →PMVP▼ -20.6%on this news
Disclaimer Forward-Looking Statements This presentation contains forward looking statements. Such statements include, but are not limited to, statements regarding our research, preclinical and clinical development activi
PMV Pharma provided an update on their investigational drug rezatapopt during an investor webinar. The Phase 2 PYNNACLE study has shown promising interim data, indicating efficacy and safety for treating patients with platinum-resistant ovarian cancer. The company plans to submit a New Drug Application (NDA) in Q1 2027 and asserts a solid financial position to support ongoing developments. However, the presentation also highlighted the inherent risks and uncertainties associated with clinical trials and regulatory approvals.
Read more →PMVP▼ -20.6%on this news
PMV Pharmaceuticals Announces Promising Rezatapopt Monotherapy Interim Data From PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation
PMV Pharmaceuticals has released promising interim data from its PYNNACLE Phase 2 clinical trial for rezatapopt, a drug targeting TP53 Y220C mutations. The trial showed a 33% overall response rate across various solid tumors, with a notable 43% in ovarian cancer. The company plans to submit a New Drug Application by early 2027. As part of its strategy, PMV Pharma aims to continue enrolling patients and will host a webinar to discuss the data and regulatory updates.
Read more →PMVPPMV Pharmaceuticals Reports Second Quarter 2025 Financial Results and Corporate Highlights • PMV will host an investor webinar on Wednesday
PMV Pharmaceuticals has reported its financial results for the second quarter of 2025, including a cash position of $148.3 million, expected to last until late 2026. The company will host a webinar on September 10, 2025, to discuss interim analysis data from the Phase 2 PYNNACLE clinical trial involving 65 patients. The net loss increased to $21.2 million, and R&D expenses rose to $18.4 million due to higher costs in advancing their lead drug, rezatapopt, which has received Fast Track designation from the FDA.
Read more →PMVPPMV Pharmaceuticals to Participate at Upcoming Investor Conferences
PMV Pharmaceuticals will participate in upcoming investor conferences, including the TD Cowen 6th Annual Oncology Innovation Summit and the Jefferies Global Healthcare Conference. CEO David H. Mack and CDO Deepika Jalota will represent the company. The events will feature live audio webcasts, with replays available for 90 days.
Read more →PMVPPMV Pharmaceuticals Reports First Quarter 2025 Financial Results and Corporate Highlights • Enrollment on track in Phase 2 pivotal portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patient
PMV Pharmaceuticals reported its financial results for Q1 2025, highlighting continued progress in the clinical trial of rezatapopt, which is being evaluated for advanced solid tumors. The company has a cash balance of $165.8 million, projected to sustain operations through late 2026. Plans for an interim analysis from the ongoing Phase 2 PYNNACLE trial are set for mid-2025, which aims to evaluate the drug's effectiveness in a specific patient population. Despite these positives, the company reported a net loss increase and rising R&D expenses, raising concerns about operational costs and future results.
Read more →PMVPPMV Pharmaceuticals Reports Full Year 2024 Financial Results and Corporate Highlights • Enrollment on track in Phase 2 pivotal portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients wi
PMV Pharmaceuticals has reported their financial results for the full year 2024 and provided key corporate updates. The company is advancing the Phase 2 pivotal portion of the PYNNACLE clinical trial evaluating rezatapopt, with enrollment on track across numerous sites globally. They announced a collaboration with major cancer centers for new studies on patients with specific mutations and reported promising results from interim analyses. However, PMV has halted enrollment in the combination arm of one study due to insufficient benefit from treatment.
Read more →PMVP▲ +7.2%on this news
PMV Pharmaceuticals Reports Third Quarter 2024 Financial Results • Enrollment on track in Phase 2 portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and KRAS wild-t
PMV Pharmaceuticals announced its financial results for Q3 2024 and provided an update on the PYNNACLE Phase 2 clinical trial, which is progressing well, with enrollment and site activation on track. The company reported a strong cash position of approximately $197.9 million, which is expected to support operations through the end of 2026. Despite an increase in net loss due to higher research and development costs, PMV Pharma is collaborating with leading oncology research institutions to further evaluate its lead drug candidate, rezatapopt, in various cancer treatments.
Read more →PMVP▼ -6.4%on this news
PMV Pharmaceuticals Provides a Progress Update on PYNNACLE Clinical Trial
PMV Pharmaceuticals has provided an update on its PYNNACLE clinical trial, reporting that enrollment for the Phase 2 monotherapy portion is progressing well, with over 75% of sites activated across the U.S., Europe, and Asia-Pacific. An interim analysis of the trial is expected by mid-2025, with plans to submit a New Drug Application by the end of 2026. However, due to dose-limiting toxicities and lack of clinical benefit in the Phase 1b combination arm with pembrolizumab, PMV has decided to discontinue this portion of the trial. The company is collaborating with major cancer centers to initiate a Phase 1b study for AML/MDS patients using rezatapopt in other combinations.
Read more →PMVPPMV Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides a Progress Update on PYNNACLE Clinical Trial • Enrollment on track in Phase 2 portion of PYNNACLE clinical trial evaluating rezatapopt
PMV Pharmaceuticals reported its second quarter 2024 financial results, highlighting encouraging enrollment rates in the Phase 2 portion of its PYNNACLE clinical trial for rezatapopt. With 60% of trial sites activated globally, the company anticipates an interim analysis by mid-2025 and aims for a New Drug Application filing by the end of 2026. Financially, PMV concluded the period with $212.9 million in cash and reduced net loss compared to the previous year, although challenges remain in the clinical trial regarding dose-limiting toxicities.
Read more →PMVPPMV Pharmaceuticals to Participate at Upcoming Investor Conferences in June
PMV Pharmaceuticals, a precision oncology company, has announced its participation in two major investor conferences in June 2024. CEO David H. Mack and CDO Deepika Jalota will take part in fireside chats at the Jefferies Global Healthcare Conference and the Goldman Sachs Annual Global Healthcare Conference. These events will provide opportunities for one-on-one investor meetings and include live webcasts for broader access. The company focuses on developing tumor-agnostic therapies targeting p53, a protein significant in cancer biology.
Read more →PMVPPMV Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Highlights • First patient dosed in Phase 2 portion of the PYNNACLE trial which will assess rezatapopt as monotherapy in patients with
PMV Pharmaceuticals reported its first quarter 2024 financial results, highlighting the dosing of the first patient in the Phase 2 PYNNACLE trial for rezatapopt, a treatment for advanced solid tumors. The trial aims to evaluate the drug's efficacy as a monotherapy in patients with specific TP53 mutations. The company presented promising Phase 1 data for rezatapopt in advanced ovarian cancer. Despite a solid cash position of $213.1 million, PMV Pharma experienced a net loss and increased operational costs in the past quarter.
Read more →PMVPPMV Pharmaceuticals Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220C-Positive Solid Tumors
PMV Pharmaceuticals announced the dosing of the first patient in its Phase 2 PYNNACLE trial evaluating rezatapopt for patients with advanced solid tumors possessing the TP53 Y220C mutation. This marks a significant advancement in PMV's efforts to develop targeted therapies for specific cancer mutations. The trial will assess rezatapopt as a monotherapy and aims to enroll 114 patients across multiple sites globally. The drug has received Fast Track designation from the FDA, reflecting its potential importance in treating these tumors.
Read more →PMVP▼ -5.1%on this news
PMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual Meeting on Women’s Cancer
PMV Pharmaceuticals presented Phase 1 data from the PYNNACLE study at the 2024 SGO Annual Meeting, demonstrating promising efficacy of rezatapopt in patients with advanced ovarian cancer carrying the TP53 Y220C mutation. In the efficacy evaluable cohort, seven out of 15 patients achieved a confirmed partial response, with a median duration of response lasting seven months. The therapy was noted for its favorable safety profile, and PMV plans to advance to Phase 2 trials in patients with this specific mutation as part of its ongoing clinical development.
Read more →PMVPPMV Pharmaceuticals Reports Full Year 2023 Financial Results and Corporate Highlights • Registrational, tumor-agnostic Phase 2 portion of PYNNACLE clinical trial of rezatapopt (PC14586), a first-in-class precision
PMV Pharmaceuticals has reported its financial results for the full year of 2023, highlighting significant developments in its precision oncology pipeline, particularly with rezatapopt. The company is progressing towards initiating a Phase 2 clinical trial for this investigational therapy aimed at patients with specific genetic mutations. Cash reserves and strategic cost reductions suggest financial stability through 2026, while recent clinical data demonstrates promising response rates across various cancers. Key organizational changes have been implemented to bolster the development efforts for rezatapopt.
Read more →PMVP▲ +7.8%on this newsshared move
PMV Pharmaceuticals to Participate in the TD Cowen 44th Annual Health Care Conference
PMV Pharmaceuticals, Inc. will participate in the TD Cowen 44th Annual Health Care Conference from March 4-6, 2024, in Boston, Massachusetts. David Mack, Ph.D., CEO, is set to engage in a fireside chat during the event, which emphasizes PMV's innovative work in oncology. Attendees will also have the opportunity for one-on-one meetings with the company. PMV Pharma specializes in small molecule therapies targeting p53 mutations, which are prevalent in many cancers.
Read more →PMVP▼ -5.8%on this news
PMV Pharmaceuticals Announces Prioritization of PC14586 Clinical Development and Extended Cash Runway
PMV Pharmaceuticals announced a significant workforce reduction of around 30% as part of its strategy to prioritize the clinical development of PC14586. This decision is expected to enhance the company's operational efficiency and extend its cash runway to the end of 2026, supported by $229 million in cash and equivalents. The registrational Phase 2 clinical trial for PC14586 is set to initiate in the first quarter of 2024. However, the company will incur significant one-time costs related to employee severance.
Read more →PMVP▼ -5.9%on this news
PMV Pharmaceuticals Strengthens Leadership with Key Appointments as Company Advances into Late-Stage Development PC14586 clinical program to be led by Deepika Jalota, Pharm.D. (Chief Development Officer) and Marc Fellous
PMV Pharmaceuticals announced key leadership appointments, including Deepika Jalota as Chief Development Officer, as the company progresses its PC14586 clinical program into late-stage development. With the recent FDA Fast Track designation for PC14586, a small molecule aimed at reactivating p53 mutations in solid tumors, the company is positioned for growth. The new roles are expected to leverage significant expertise in oncology and drug approvals, marking a pivotal moment for PMV as it transitions to this next phase.
Read more →PMVPPMV Pharmaceuticals Announces Prioritization of PC14586 Clinical Development and Extended Cash Runway Prioritization of PC14586 development and focused discovery research efforts results in a workforce reduction of appro
PMV Pharmaceuticals has announced a strategic workforce reduction of approximately 30% to prioritize the clinical development of PC14586, a drug targeting p53 mutations found in many cancers. This decision is expected to extend the company's cash runway until the end of 2026, after reporting $229 million in cash and equivalents as of the end of 2023. The FDA has granted Fast Track designation to PC14586, indicating its potential in treating locally advanced or metastatic solid tumors with a specific mutation. While this streamlining aims to enhance operational efficiency, it does come with significant one-time charges related to severance costs.
Read more →PMVPPMV Pharmaceuticals, Inc. Condensed Statements of Opera tions and Comprehensive Loss (unaudited) (in thousands, except share and per share amounts) Three Months Ended September 30, Nine Months Ended
PMV Pharmaceuticals, Inc. announced its third quarter 2023 financial results and provided updates on its clinical trials, particularly for PC14586. Updated findings from the Phase 1 PYNNACLE trial showed a 38% overall response rate and a median response duration of seven months across various tumor types. The company plans to initiate a registrational Phase 2 trial in the first quarter of 2024 and continues its collaboration with Merck for an ongoing clinical study. However, PMV recorded a net loss of $53.2 million for the nine months ended September 30, 2023, highlighting financial challenges as R&D expenses rise.
Read more →PMVPPMV Pharmaceuticals Reports Third Quarter 2023 Financial Results and Corporate Highlights
PMV Pharmaceuticals reported encouraging results from its Phase 1 PYNNACLE clinical trial, showcasing a 38% overall response rate for its drug PC14586 in patients with specific tumor types. The trial's median duration of response was established at seven months, suggesting significant efficacy across various solid tumors. The company is set to commence a registrational Phase 2 study in early 2024, building on these positive findings. Additionally, PMV ended Q3 2023 with a substantial cash reserve of $238.1 million, positioning it well for future clinical developments.
Read more →PMVP▼ -47.6%on this news· ran to -59% by day 3
PMV Pharmaceuticals Updated PC14586 Phase 1 Data Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With a TP53 Y220C Mutation Updated PC14586 Phase 1 data presented today as a late-breaking poster at 202
PMV Pharmaceuticals announced updated Phase 1 results for its investigational therapy PC14586, which demonstrated efficacy in patients with advanced solid tumors harboring a TP53 Y220C mutation. The data, presented at the AACR-NCI-EORTC International Conference, showcased a favorable safety profile and contributed to the design of a Phase 2 registrational trial set to commence in early 2024. This study aims to address the significant unmet needs of patients with these mutations, as currently there are no approved therapies targeting p53.
Read more →PMVP▼ -26%on this news· ran to -72% by day 3shared move
PMV Pharmaceuticals to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics and Host a KOL Webinar PRINCETON, N.J.
PMV Pharmaceuticals has announced the presentation of updated Phase 1 data on its experimental therapy, PC14586, during the 2023 AACR-NCI-EORTC conference. This therapy targets advanced solid tumors with a TP53 Y220C mutation and aims to provide new treatment options for patients. The data will be discussed in detail through a poster session and a webinar, reflecting the company's commitment to sharing developments in their clinical research. The FDA's Fast Track designation for PC14586 suggests its promising potential in oncology.
Read more →PMVP▲ +9.6%on this news
PMV Pharmaceuticals to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
PMV Pharmaceuticals announced that updated Phase 1 clinical data for its investigational therapy PC14586 will be presented at the 2023 AACR-NCI-EORTC conference in Boston. This therapy is focused on treating patients with advanced solid tumors that have a TP53 Y220C mutation. Additionally, the company will host a webinar to discuss the data and provide a regulatory update. The PYNNACLE study aims to determine the maximum tolerated dose of PC14586 and evaluate its efficacy.
Read more →PMVP▲ +27.7%on this news
PMV Pharmaceuticals Reports Second Quarter 2023 Financial Results and Corporate Highlights • Continued progress in ongoing Phase 1/2 PYNNACLE study of PC14586, a first-in-class precision oncology investigational t
PMV Pharmaceuticals has reported its financial results for the second quarter of 2023, highlighting progress in the Phase 1/2 PYNNACLE study of PC14586, a precision oncology therapy targeting p53 Y220C mutations in advanced solid tumors. The company successfully concluded an End-of-Phase 1 meeting with the FDA, achieving alignment on the Phase 2 dose and study design. PMV plans to initiate the Phase 2 study in early 2024 and announced the appointment of Dr. Masha Poyurovsky as Vice President of Biology to enhance their research capabilities.
Read more →PMVP▲ +7.6%on this news
PMV Pharmaceuticals to Participate in the Goldman Sachs Global Healthcare Conference
PMV Pharmaceuticals, a leader in precision oncology, announced its participation in the Goldman Sachs Global Healthcare Conference. CEO David H. Mack will take part in a fireside chat scheduled for June 13, 2023, in Dana Point, California. The company aims to engage with institutional investors at the event, highlighting its innovative work on tumor-agnostic therapies targeting p53, a protein involved in many cancers.
Read more →PMVP▲ +8.3%on this news
PMV Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate Highlights • Continued progress in the ongoing Phase 1/2 PYNNACLE study of PC14586, a first-in-class precision oncology investigationa
PMV Pharmaceuticals has reported its first-quarter 2023 financial results, highlighting progress in the Phase 1/2 PYNNACLE study of its oncology drug PC14586 for patients with a p53 Y220C mutation. The company has begun enrollment for a combination treatment with KEYTRUDA and aims to provide updates later in the year. Financially, PMV reported a net loss of $19.1 million, an increase from the previous year, alongside rising research and development expenses. The company holds $229.4 million in cash and equivalents.
Read more →PMVP▼ -14.1%on this news
PMV Pharmaceuticals Reports Full Year 2022 Financial Results and Corporate Highlights • Continued progress in ongoing Phase 1/2 PYNNACLE study of PC14586, a first-in-class precision oncology investigational therap
PMV Pharmaceuticals reported its full year 2022 financial results, highlighting significant advances in its ongoing Phase 1/2 PYNNACLE study of PC14586, targeting advanced solid tumors with p53 mutations. The company successfully enrolled the first patient in a combination trial with KEYTRUDA and showcased strong preliminary data from its studies. Despite a growing cash reserve of $243.5 million, PMV also noted an increased net loss and rising research expenses compared to the previous year. The company plans to provide updates on clinical trial progress and a recommended Phase 2 dose in the latter half of 2023.
Read more →PMVPPMV Pharmaceuticals to Participate at Upcoming Investor Conferences in March
PMV Pharmaceuticals has announced its participation in two investor conferences in March 2023, with CEO David H. Mack set to represent the company. The company's focus is on precision oncology and the development of tumor-agnostic therapies targeting p53. The conferences include the Cowen's 43rd Annual Health Care Conference and Oppenheimer's 33rd Annual Healthcare Conference, providing a platform to discuss their innovative approaches in cancer treatment.
Read more →PMVP▲ +5%on this news
PMV Pharmaceuticals to Participate in the 5th Annual Evercore ISI HealthCONx Conference
CRANBURY, N.J., Nov. 22, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP; “PMV Pharma”), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that David H. Mack, Ph.D., Pr
Read more →PMVPPMV Pharmaceuticals Reports Third Quarter 2022 Financial Results and Corporate Highlights • Enrollment continued in the Phase 1/2 PYNNACLE study of PC14586, a first-in-class precision oncology investigational ther
PMV Pharmaceuticals Reports Third Quarter 2022 Financial Results and Corporate Highlights -Enrollment continued in the Phase 1/2 PYNNACLE study of PC14586, a first-in-class precision oncology investigational therapy in patients with advanced solid tumors with a p53 Y220C mutatio
Read more →PMVPPMV Pharmaceuticals Appoints Industry Veteran Dr. Carol Gallagher to Board of Directors CRANBURY, N.J.
PMV Pharmaceuticals Appoints Industry Veteran Dr. Carol Gallagher to Board of Directors CRANBURY, N.J., November 4, 2022 (GLOBE NEWSWIRE) PMV Pharmaceuticals, Inc. ( PMV Pharma or PMV ; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of smal
Read more →PMVP▼ -8.1%on this news
PMV Pharmaceuticals Reports Second Quarter 2022 Financial Results and Corporate Highlights • Initial PC14586 Phase 1 data presented at the American Society of Clinical Oncology Annual Meeting (ASCO) demonstrated r
PMV Pharmaceuticals Reports Second Quarter 2022 Financial Results and Corporate Highlights -Initial PC14586 Phase 1 data presented at the American Society of Clinical Oncology Annual Meeting (ASCO) demonstrated responses in patients across multiple solid tumor types with a p53 Y
Read more →PMVP▼ -9.5%on this news
PMV Pharmaceuticals Announces a Clinical Trial Collaboration with Merck to Evaluate PC14586 in Combination with KEYTRUDA (pembrolizumab) in Patients with Advanced Solid Tumors
CRANBURY, N.J., July 18, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP; “PMV Pharma”), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that it has entered into a cl
Read more →PMVP▼ -21.7%on this newsshared move
PMV Pharmaceuticals Initial PC14586 Phase 1 Data Presented at ASCO Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With a p53 Y220C Mutation Overall response rate (ORR) of 32% (8/25) achieved in higher
PMV Pharmaceuticals Initial PC14586 Phase 1 Data Presented at ASCO Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With a CRANBURY, N.J., June 7, 2022 (GLOBE NEWSWIRE) PMV Pharmaceuticals, Inc. (Nasdaq: PMVP; PMV Pharma ), a precision oncology company pioneer
Read more →PMVPPMV Pharmaceuticals Announces Initial PC14586 Phase 1 Clinical Data to be Presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting Preliminary results represent the first clinical evidence of tar
PMV Pharmaceuticals Announces Initial PC14586 Phase 1 Clinical Data to be Presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting CRANBURY, N.J., May 26, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP; "PMV Pharma"), a precision oncolo
Read more →PMVP▲ +9.7%on this news
PMV Pharmaceuticals Reports First Quarter 2022 Financial Results and Corporate Highlights Oral presentation at 2022 ASCO annual meeting to highlight initial data from ongoing Phase 1/2 PYNNACLE study of PC14586 in patien
PMV Pharmaceuticals Reports First Quarter 2022 Financial Results and Corporate Highlights CRANBURY, N.J., May 10, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agn
Read more →PMVPPMV Pharmaceuticals to Present PC14586 Phase 1 Clinical Data at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
Oral presentation at ASCO to highlight initial data from ongoing Phase 1 study of PC14586, a first-in-class precision oncology investigational therapy, in patients with advanced solid tumors that have a p53 Y220C mutation CRANBURY, N.J., April 27, 2022 (GLOBE NEWSWIRE) -- PMV Ph
Read more →PMVP▲ +5.1%on this news
PMV Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights Continued progress with Phase 1/2 study of PC14586, a first-in-class precision oncology investigational therapy in
PMV Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights CRANBURY, N.J., March 01, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small mo
Read more →PMVPPMV Pharmaceuticals to Participate in the 42nd Annual Cowen Health Care Conference
CRANBURY, N.J., Feb. 28, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that David H. Mack, Ph.D., President & Chi
Read more →PMVPPMV Pharmaceuticals to Participate in the Guggenheim Healthcare Talks 2022 Oncology Day
CRANBURY, N.J., Feb. 03, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants, today announced that David H. Mack, Ph.D., Presiden
Read more →PMVP▼ -16.3%on this news
PMV Pharma Announces Changes to its Board of Directors CRANBURY, NJ
PMV Pharma Announces Changes to its Board of Directors CRANBURY, NJ, January 06, 2022 (GLOBE NEWSWIRE) PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutat
Read more →PMVPPMV Pharma to Present at the Evercore ISI 4th Annual HealthCONx Conference
CRANBURY, N.J., Nov. 22, 2021 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants, today announced that David H. Mack, Ph.D., Presiden
Read more →PMVPPMV Pharmaceuticals Reports Third Quarter 2021 Financial Results and Corporate Highlights
CRANBURY, N.J., Nov. 12, 2021 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a clinical-stage oncology company pioneering the discovery and development of small molecule therapies designed to activate p53 function, today reported financial results for the third qua
Read more →PMVPPMV Pharmaceuticals, Inc. Condensed Statements of Operations and Comprehensive Loss (unaudited) (in thousands, except share and per share amounts) Three Months Ended September 30, Nine Months Ended
PMV Pharmaceuticals Reports Third Quarter 2021 Financial Results and Corporate Highlights CRANBURY, NJ, November 12, 2021 (GLOBE NEWSWIRE) - PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a clinical-stage oncology company pioneering the discovery and development of small molecule the
Read more →PMVPPMV Pharmaceuticals Appoints Tim Smith as Senior Vice President, Head of Corporate Development
CRANBURY, N.J., Sept. 09, 2021 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants, today announced the appointment of Tim Smith as Se
Read more →PMVPPMV Pharmaceuticals to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
CRANBURY, N.J., Sept. 02, 2021 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants, today announced that David H. Mack, Ph.D., Preside
Read more →PMVPPMV Pharmaceuticals, Inc. Condensed Statements of Operations and Comprehensive Loss (unaudited) (in thousands, except share and per share amounts) Three Months Ended June 30, Six Months Ended
PMV Pharmaceuticals Reports Second Quarter 2021 Financial Results and Corporate Highlights CRANBURY, NJ, August 13, 2021 (GLOBE NEWSWIRE) - PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a clinical-stage oncology company pioneering the discovery and development of small molecule, tum
Read more →PMVPPMV Pharmaceuticals Reports Second Quarter 2021 Financial Results and Corporate Highlights
Continued enrollment in Phase 1/2 trial of first-in-class p53 Y220C reactivator PC14586 CRANBURY, N.J., Aug. 13, 2021 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a clinical-stage oncology company pioneering the discovery and development of small molecule, tumor
Read more →PMVPPMV Pharmaceuticals Announces Participation at the Bank of America Securities 2021 Napa Biopharma Virtual Conference
CRANBURY, N.J., June 09, 2021 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants, today announced that David H. Mack, Ph.D., Presiden
Read more →PMVPPMV Pharmaceuticals Announces Participation at the Goldman Sachs Annual Healthcare Conference
CRANBURY, N.J., June 03, 2021 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants, today announced that David H. Mack, Ph.D., Presiden
Read more →PMVPPMV Pharmaceuticals Reports First Quarter 2021 Financial Results and Corporate Highlights Presented late breaking preclinical data on PC14586, the Company's first-in-class, tumor-agnostic, investigational small molecule
PMV Pharmaceuticals Reports First Quarter 2021 Financial Results and Corporate Highlights CRANBURY, NJ, May 14, 2021 (GLOBE NEWSWIRE) - PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnost
Read more →PMVPPMV Pharmaceuticals Announces Participation at the Bank of America Healthcare Conference
CRANBURY, N.J., May 05, 2021 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants, today announced that David H. Mack, Ph.D., President
Read more →PMVPPMV Pharma Presents Late-Breaking Preclinical Data on Lead Product Candidate PC14586 at the American Association for Cancer Research Annual Meeting 2021
PC14586 selectively stabilizes the p53 Y220C mutant and restores p53 activity Robust in vivo tumor regression observed with once daily oral dosing Pharmacodynamic biomarkers of p53 activation developed for clinical trials PC14586 is being tested in a Phase 1/2 clinical trial i
Read more →PMVPPMV Pharma Strengthens Board of Directors with Appointment of Dr. Charles Baum CRANBURY, NJ
PMV Pharma Strengthens Board of Directors with Appointment of Dr. Charles Baum CRANBURY, NJ, April 6, 2021 (GLOBE NEWSWIRE) PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapie
Read more →PMVPPMV Pharmaceuticals Announces Presentation of PC14586 Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2021
CRANBURY, N.J., March 10, 2021 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants, today announced that the company will present at t
Read more →PMVPPMV Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Highlights Initiated Phase 1/2 study of PC14586, a first-in-class precision oncology investigational therapy in patients with
PMV Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Highlights CRANBURY, NJ, March 3, 2021 (GLOBE NEWSWIRE) - PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecu
Read more →PMVPPMV Pharmaceuticals Announces Participation at the Cowen 41st Annual Health Care Conference
CRANBURY, N.J., Feb. 23, 2021 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants, today announced that David H. Mack, Ph.D., Presiden
Read more →PMVPPMV Pharma Appoints p53 Pioneer Dr. Guillermina Lozano to Scientific Advisory Board
CRANBURY, N.J., Feb. 16, 2021 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants, today announced the appointment of Guillermina (Gig
Read more →PMVPPMV Pharmaceuticals to Present at Evercore ISI 3rd Annual HealthCONx Conference
CRANBURY, N.J., Nov. 24, 2020 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants, today announced that David H. Mack, Ph.D., Presiden
Read more →PMVPPMV Pharma Doses First Patient in Phase 1/2 Study of PC14586, a First-in-Class Precision Oncology Therapy That Targets Mutant p53
PC14586 targets p53 Y220C mutants to selectively reactivate p53, restoring the protein’s tumor-suppressing function Phase 1/2 study is enrolling patients with advanced solid tumors that have a p53 Y220C mutation CRANBURY, N.J., Nov. 23, 2020 (GLOBE NEWSWIRE) -- PMV Pharmaceutic
Read more →PMVPPMV Pharmaceuticals Reports Third Quarter 2020 Financial Results and Corporate Highlights
PMV Pharmaceuticals Reports Third Quarter 2020 Financial Results and Corporate Highlights CRANBURY, NJ, November 13, 2020 (GLOBE NEWSWIRE) - PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-a
Read more →PMVPPMV Pharma Granted FDA Fast Track Designation of PC14586 for the Treatment of Advanced Cancer Patients that have Tumors with a p53 Y220C Mutation
CRANBURY, N.J., Oct. 13, 2020 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc., (Nasdaq: PMVP) a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutations, today announced that the U.S. Food and Drug Admin
Read more →PMVPPMV Pharma Announces Closing of $243.5 Million Initial Public Offering and Exercise in Full of the Underwriters Option to Purchase Additional Shares CRANBURY, New Jersey
PMV Pharma Announces Closing of $243.5 Million Initial Public Offering and Exercise in Full of the Underwriters Option to Purchase Additional Shares CRANBURY, New Jersey, September 29, 2020 (GLOBE NEWSWIRE) - PMV Pharmaceuticals, Inc., a precision oncology company pioneering th
Read more →PMVPPMV Pharma Announces Pricing of Initial Public Offering
CRANBURY, N.J., Sept. 24, 2020 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc., a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutations, today announced the pricing of its initial public offering of 1
Read more →PMVPPMV Pharma Appoints Laurie Stelzer to the Board of Directors and Robert Ticktin as General Counsel
CRANBURY, N. J., Sept. 08, 2020 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc., a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutations, announced the appointments of Laurie Stelzer to the Board of D
Read more →PMVPPMV Pharma Closes $70 Million in Series D Financing
CRANBURY, N.J., Aug. 03, 2020 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc., a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutations, announced the completion of a $70 million Series D financing rou
Read more →PMVPPMV Pharma Appoints Leila Alland, M.D., as Chief Medical Officer
CRANBURY, N.J., Dec. 11, 2019 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc., a leader in the discovery and development of p53-targeted small molecule drugs for the treatment of cancer, today announced the appointment of Dr. Leila Alland, M.D., as Chief Medical Officer. Dr. Allan
Read more →Competitive Position
How PMVP ranks across every disease it competes inCompetitive Position is a premium feature
See how PMVP ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial